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The frequent coexpression of the EBV-encoded latent membrane proteins LMP1 and LMP2A/B in virus-associated tumors
suggests that these two proteins may cooperate in the transformation process. While LMP2A is unable to directly activate
the NF-kB and AP-1 pathways, we found that coexpression of LMP2A with LMP1 resulted in a significant enhancement of
LMP1-mediated activation of these pathways. This enhancement was found to be critically dependent on the tyrosine
residues present within the ITAM motif (Y74/Y85) and, to a lesser extent, the tyrosine at position 112 (Y112). Subsequent
analysis revealed that LMP2A is able to stabilize and modulate the turnover of LMP1 by extending its half-life. This ability
does not require a direct physical interaction between the two proteins but rather, results from an indirect effect of LMP2A
on the turnover of the LMP1 protein. This study highlights an important role for LMP2A as a modulator of LMP1 activity in
epithelial cells. © 2001 Academic Press
iINTRODUCTION
Epstein–Barr virus (EBV) is a ubiquitous human her-
pesvirus that is causally associated with the tumors of B
cell origin (Burkitt’s lymphoma, immunoblastic lym-
phoma, Hodgkin’s disease) and epithelial cell origin (na-
sopharyngeal carcinoma, gastric adenocarcinomas)
(Rickinson and Kieff, 1996). The exact contribution of EBV
to the development of nasopharyngeal carcinoma (NPC)
and other carcinomas is unclear as is the stage in the
oncogenic process at which EBV infection of epithelial
cells occurs. However, both NPC and EBV-positive gas-
tric carcinoma tumor cells carry monoclonal viral ge-
nomes, indicating that EBV infection must have occurred
prior to expansion of the malignant cell clone (Imai et al.,
1994; Raab-Traub, 1992). A novel form of virus:cell inter-
action has been demonstrated in NPC and Hodgkin’s
disease (HD) tumor cells, with the pattern of viral gene
expression being predominantly restricted to Epstein–
Barr nuclear antigen 1 (EBNA1) and the latent membrane
proteins (LMP1, LMP2A, and LMP2B) (Brooks et al., 1992;
Deacon et al., 1993).
LMP1 is the major transforming protein of EBV and
displays classical oncogene activity by virtue of its ability
to transform rodent fibroblasts (Kieff, 1996). In both B
cells and epithelial cells, the effects of LMP1 expression
on cellular phenotype has been examined and the sig-
naling pathways engaged by LMP1 elucidated in great
detail (Eliopoulos and Rickinson, 1998; Kieff, 1996; Mo-
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192sialos et al., 1995). LMP1 self-associates in the plasma
membrane and contains distinct domains within its iden-
tified cytoplasmic C terminus, which binds and engages
signaling proteins (Floettmann and Rowe, 1997; Mosia-
los et al., 1995). Two distinct signaling domains, desig-
nated C-terminal activation domains 1 and 2 (CTAR 1 and
CTAR2), have been identified in the cytoplasmic tail of
LMP1 (Devergne et al., 1996; Huen et al., 1995). These
regions bind tumor necrosis factor (TNF) associated fac-
tors (TRAFs) and TNF receptor death domain protein
(TRADD), which initiate signaling to the transcription
factors NF-kB and AP-1 through distinct pathways (Dev-
ergne et al., 1996, 1998; Eliopoulos et al., 1999; Eliopou-
los and Young, 1998; Izumi et al., 1997; Izumi and Kieff,
1997; Kieser et al., 1997). NF-kB activation from CTAR1
nvolves TRAFs 1, 2, 3, and 5 and the NIK-IKK-IkB path-
way, whereas NF-kB activation from CTAR2, although
requiring TRAFs (TRAF2), is mediated through TRADD
(Devergne et al., 1998; Eliopoulos et al., 1999; Sylla et al.,
1998). AP-1 is activated through the JNK pathway via
CTAR2-binding TRADD and TRAF2 proteins and LMP1
also induces activation of the p38 MAP kinase via both
CTAR1 and CTAR2 (Eliopoulos et al., 1999a,b). As well as
its association with TRAFs, signal transduction by LMP1
shows other similarities with the ligated TNF receptor
(TNFR) response. For example, both ligation of CD40 (a
TNFR superfamily member) and LMP1 expression up-
regulate CD54 (ICAM-1) and cytokine production (IL-6,
IL-8) in B cells and epithelial cells and also induce
growth inhibition in a number of epithelial carcinoma cell
lines (Eliopoulos et al., 1996, 1997). Recent work has
shown that the JAK/STAT pathway is also activated by
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193LMP2A AUGMENTS LMP1 SIGNALINGLMP1 and that this effect is mediated via the repeat
region upstream of CTAR2 (Gires et al., 1999).
In contrast, much less is known about the function of
LMP2A/B in epithelial cells. LMP2 is a hydrophobic
membrane protein that exists as two alternative forms,
LMP2A and LMP2B (Kieff, 1996; Longnecker, 2000).
These are transcribed across the fused terminal repeats
of the EBV episome from promoters 3 kb apart which
generate mRNAs with eight common exons, and a 59
xon unique to each type. The 59 exon of LMP2B is
noncoding, whereas the 59 exon of LMP2A encodes a
119 amino acid cytoplasmic domain which is implicated
in cell signaling; this cytoplasmic domain is absent from
LMP2B, which initiates at a methionine 120 amino acids
into the LMP2A coding region. The proteins share other
structural properties including 12 hydrophobic mem-
brane-spanning domains and a 27 amino acid cytosolic
carboxyl terminus. The consistent detection of LMP2A/B
in EBV-associated malignancies such as HD, NPC, and
gastric adenocarcinoma suggests a role for LMP2A/B in
oncogenesis (Brooks et al., 1992; Busson et al., 1992;
Deacon et al., 1993; Sugiura et al., 1996). Following its
assignation as an integral membrane protein, initial stud-
ies demonstrated that LMP2A/B colocalized with LMP1
in small membrane patches in LCLs (Longnecker and
Kieff, 1990). Further investigation revealed that LMP2A/B
not only localized to the plasma membrane in B cells, but
was also broadly distributed among intracellular mem-
branes (Longnecker and Kieff, 1991). Most of the func-
tional investigations of LMP2A/B have been performed in
B cells using recombinant EBV and indicate that
LMP2A/B is dispensable for B cell transformation in vitro
(Longnecker et al., 1993a,b; Speck et al., 1999). However,
LMP2A has been suggested to regulate viral reactivation
from latency by negatively regulating B cell receptor
(BCR) signal transduction (Miller et al., 1994). BCR sig-
naling is mediated by the activation of src family and syk
protein tyrosine kinase (PTK) pathways, resulting in the
elevation of intracellular calcium levels and gene tran-
scription, driving B cell proliferation and differentiation
(Longnecker, 2000). EBV-negative BL cell lines stably
expressing LMP2A show substantially reduced calcium
mobilization upon BCR cross-linking, whereas LMP2-null
EBV recombinants trigger a wild-type PTK cascade
(Miller et al., 1994). The ability of LMP2A to inhibit BCR
signal transduction results from the presence of a puta-
tive ITAM motif (Y47/Y85) located within the cytosolic
amino terminus, which when phosphorylated recruits
and activates src and syk PTKs. LMP2A is also a sub-
trate of these kinases, including the src family PTKs,
specially lyn (Beaufils et al., 1993; Burkhardt et al.,
992). Recent work has highlighted the role of lyn kinase
n associating with LMP2A via tyrosine 112 and thereby
irecting the phosphorylation of the ITAM motif (Frueh-
ing et al., 1998). This subsequently results in the recruit-
ent of PTKs to LMP2A, possibly sequestering these
nzymes away from the BCR signaling complex, thusenerating a block (Fruehling et al., 1998). Recent data
uggest that LMP2A may recruit ubiquitin–protein li-
ases, and therefore target any bound PTKs for degra-
ation (Ikeda et al., 2000). Other tyrosine residues (Y31,
60, and Y101) within LMP2A show homology with SH2
inding sites for proteins such as PI-3K, Abl, and Csk, but
irect interactions have not been demonstrated (Long-
ecker, 2000). However, tyrosines 60, 64, and 101 are not
ssential for blocking BCR signal transduction and in
ddition, tyrosine residues do not appear to affect ex-
ression levels or localization of LMP2A (Fruehling et al.,
996; Swart et al., 1999). LMP2A is also phosphorylated
n serine and threonine residues and may possess other
ritical signaling domains. In vitro, serines 15 and 102
re phosphorylated by mitogen-activated protein kinases
MAP kinases), and Erk1 directly interacts with LMP2A
Panousis and Rowe, 1997). However, the functional sig-
ificance of this association is not known. The LMP2
equence is generally conserved between EBV strains
nd many functional properties (e.g., transcriptional reg-
lation, tyrosine phosphorylation, and kinase interaction)
re conserved between the LMP2 homologues in EBV
nd herpesvirus papio (Bussson et al., 1995; Franken et
l., 1995). Recent evidence has shown that the expres-
ion of LMP2A in the B cells of transgenic mice provides
developmental and survival signal that bypasses the
equirement for BCR signaling (Caldwell et al., 2000,
998). This suggests that LMP2A can drive B cell prolif-
ration independent of BCR signaling and is consistent
ith the proposed role of LMP2A in the establishment of
ersistent B cell infection (Thorley-Lawson, 1999).
Despite extensive study in the B cell system, LMP2A
nd LMP2B are both expressed in EBV-associated car-
inomas (NPC and gastric adenocarcinomas) and in
umors of lymphoid origin (HD and immunoblastic lym-
homas) (Brooks et al., 1992; Busson et al., 1992; Deacon
t al., 1993; Niedobitek et al., 1997; Rickinson and Kieff,
996; Sugiura et al., 1996). It is possible that the role of
MP2A/B is altered in different cell backgrounds as com-
ared to EBV-transformed LCLs. However, little is known
bout the effect of LMP2A/B on epithelial cell function.
he phosphorylation of LMP2A in epithelial cells is trig-
ered by cell adhesion, but this does not appear to be
ediated via src kinases (Scholle et al., 1999). It is
peculated that this phosphorylation is due to C-terminal
rc kinase (Csk, a negative regulator of src kinases),
hich contains a SH2 domain and has a consensus
binding site at tyrosine 101 of LMP2A. Csk has been
shown to interact with components of the cytoskeleton,
including Fak and paxillin, and this provides a mecha-
nism whereby LMP2A may influence cell adhesion
(Tremblay et al., 1996). In addition, both LMP2A and
LMP2B have been shown to alter the expression of
keratinocyte adhesion molecules and as this effect is
ECM nonspecific, it has been suggested that the het-
erodimeric integrin family of cell surface molecules may
be involved (Farwell et al., 1999; Scholle et al., 1999). The
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194 DAWSON ET AL.frequent coexpression of LMP2 with LMP1 in EBV-asso-
ciated tumors, coupled with their overall similarities in
structure, has lead to speculation that these two proteins
may cooperate or interact in some way. Using a combi-
nation of transient transfection assays and stable epithe-
lial cell lines in which LMP1 is coexpressed with LMP2A
or LMP2B, we demonstrate that LMP2A can modulate
LMP1 signaling and that this effect is not a consequence
of direct interactions between the two proteins. This
piece of data has important implications for our under-
standing of the role of LMP2A in the pathogenesis of
EBV-associated malignancies.
RESULTS
Stable expression and cellular localization of LMP2A
and LMP2B in epithelial cells
Stable, polyclonal epithelial cell lines expressing
LMP2A and LMP2B were generated by retroviral trans-
duction of the A431 and EJ cell lines. After expansion
under G418 selection, polyclonal cell lines were
screened for expression by immunoblotting and immu-
nostaining. Expression of LMP2A in transduced EJ and
A431 cell lines was confirmed by immunoblotting with
the LMP2A-specific rat monoclonal antibody (mAb), 14B7
(Fig. 1). No expression was detected in either vector
control lines or in cells transduced with the LMP2B
retrovirus (Fig. 1). To examine the distribution of LMP2A
and LMP2B in epithelial cells, stable clones of A431 cells
expressing LMP2A and LMP2B were immunostained in
itu with a selected human serum, Ba (obtained from an
PC patient), that displays reactivity for both LMP2A and
MP2B (Lennette et al., 1995; our own unpublished data).
mmunostaining of vector control A431 cells with Ba
erum (Fig. 2A) showed only background levels of non-
pecific staining. In marked contrast, cells expressing
ither LMP2A (Fig. 2B) or LMP2B (Fig. 2C) displayed
unctate perinuclear reactivity when stained with the
MP2A/B-specific Ba serum, whereas only background
taining was observed with the EBV-seronegative serum
n LMP2A-expressing A431 cells (Fig. 2D). Identical
MP2A/B staining patterns were observed in transduced
FIG. 1. Stable expression of LMP2A or LMP2B in epithelial cell lines.
EJ and A431 cells stably transduced with LMP2A, LMP2B, or the neo
retrovirus were blotted for LMP2A expression using the LMP2A-spe-
cific monoclonal antibody, 14B7. Cos-1 cells transiently transfected with
a pSG5LMP2A expression vector served as a positive control.J cells (data not shown).
The finding that most if not all of LMP2A and LMP2BFIG. 2. LMP2A and LMP2B localize to intracellular vesicles in
epithelial cells. A431 cells transduced with LMP2A, LMP2B, or the
neo retrovirus were grown on glass microscope slides for 48 h and
processed for immunostaining in situ. Immunostaining for LMP2A/B
with an NPC reference serum (Ba) showed only background levels
of staining on neo control cells (A), whereas staining of both LMP2A
(B) and LMP2B-expressing cells (C) showed clear reactivity. Immu-
nostaining of LMP2A-expressing cells with an EBV seronegative
serum gave only background levels of staining.
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195LMP2A AUGMENTS LMP1 SIGNALINGwas localized to intracellular membranes prompted a
more thorough investigation of the exact subcellular lo-
cation of these proteins in epithelial cells using confocal
microscopy on A431 cells stably expressing LMP2A or
LMP2B. In conjunction with a panel of mAbs specific for
distinct cellular organelles, dual immunofluorescence
staining was performed with the LMP2-specific Ba ref-
erence serum. No differences were observed in the dis-
tribution of either LMP2A/B or the cellular organelles
when LMP2A/B or the membrane markers were stained
singly, and the membrane markers showed the same
distribution in the control A431-neo cells (not shown).
Figure 3 depicts dual staining on A431-LMP2A cells with
LMP2A visualized with green fluorescence (FITC-conju-
gated secondary antibody) and the various membrane
markers with red fluorescence (TRITC-conjugated sec-
ondary antibodies); therefore, any colocalization be-
tween LMP2A and these markers is seen as yellow
fluorescence. Significant colocalization between LMP2A
and the TM4 protein CD63, a late endosome/lysosome
marker, was observed (Fig. 3C). Colocalization of LMP2A
with a lysosomal TM4 protein was also evident (Fig. 3F),
although the extent of this colocalization was clearly not
as marked as for CD63. Similarly, limited overlap with
staining for the 58K subunit of the Golgi apparatus was
also observed (Fig. 3I). Plasma membrane staining was
identified using an antibody to an integrin-associated
TM4 protein (CD151) which localizes predominantly at
the plasma membrane (Berditchevski et al., 1996). The
distributions of this protein and LMP2A were markedly
different (Fig. 3L), which is consistent with the observa-
tion that in epithelial cells, LMP2A has an internal mem-
brane localization and does not appear to localize in
plasma membrane patches (Longnecker and Kieff, 1990;
Winberg et al., 1996). Dual staining for LMP2A and either
mitochondria (mAb to monoamine oxidase) or the cyto-
plasmic pool of vinculin, a focal adhesion-associated
protein, failed to identify colocalization (data not shown).
The pattern of subcellular distribution of LMP2B was
identical to that of LMP2A with predominant colocaliza-
tion to the endosomal and lysosomal compartments
(data not shown). To confirm that the subcellular distri-
bution of LMP2A/B observed with the Ba reference se-
rum was not an artifact, HA-tagged versions of LMP2A
and LMP2B were introduced transiently into SVK cells
and these prepared for immunocytochemical staining.
Identical patterns of staining were observed for both
LMP2A and LMP2B when SVK cells were immuno-
stained with 12CA5, a mAb specific for the HA “flu”
epitope (data not shown).
LMP2A and LMP2B localize to regions within
epithelial cells that are distinct from LMP1
Previous work in B cells had concluded that LMP2A/B
was localized to internal cytoplasmic membranes with
some evidence of colocalization with LMP1 at “patches”
Nin the plasma membrane (Longnecker and Kieff, 1990).
To determine whether LMP2A localized to similar re-
gions of the cell as LMP1, we examined the possible
colocalization of LMP2A with LMP1 in A431 epithelial
cells. Stable A431 clones expressing LMP2A, LMP2B, or
the neomycin resistance cassette were transduced with
an amphotrophic retrovirus expressing LMP1 (B95.8
strain). After expansion under hygromycin selection,
polyclonal cell lines were generated and subsequently
expanded for further analysis. Dual immunofluorescence
staining was performed on A431 LMP1/LMP2A or LMP1/
LMP2B cell lines using the Ba reference serum to stain
for LMP2A or LMP2B, and the CS1-4 mAb to stain for
LMP1 (Fig. 4). Although both LMP1 and LMP2A or
LMP2B exhibit punctate perinuclear staining, there is
negligible colocalization in either LMP1/LMP2A- (Fig. 4B)
or LMP1/LMP2B- (Fig. 4C) expressing cells. The distri-
bution of LMP1 (Fig. 4A) was unaffected by the expres-
sion of LMP2A or LMP2B. The distribution of LMP2A and
LMP2B when stained singly in the coexpressing lines
was not significantly different to that seen in the dual
stained cells and there was no detection of protein when
the cells were stained with an EBV-negative serum (data
not shown).
LMP2A, but not LMP2B, augments LMP1-mediated
signal transduction
As LMP2A and LMP2B are frequently coexpressed
with LMP1, the possibility that the LMP2 proteins may
modulate or influence LMP1 function warranted investi-
gation. Initially, experiments were performed to investi-
gate whether LMP2A and LMP2B were, similar to LMP1,
able to activate the NF-kB and AP-1 pathways. In tran-
siently transfected SVK epithelial cells, LMP1 induced a
dose-dependent activation of the NF-kB luciferase re-
orter (Fig. 5A) but no such effect was seen with either
MP2A (Fig. 5B) or LMP2B alone (Fig. 5C). To study any
ossible cooperative effects of LMP2A and LMP2B on
MP1-induced NF-kB activation, transient reporter as-
says were performed using a suboptimal dose of LMP1
plasmid (0.1 mg) together with either LMP2A or LMP2B.
s expected the control pSG5 vector and both LMP2A
nd LMP2B failed to induce NF-kB activation alone,
whereas LMP1 gave a robust activation (Fig. 5D). How-
ever, when LMP2A was coexpressed with LMP1, an
almost twofold enhancement of NF-kB activation was
bserved, whereas coexpression with LMP2B failed to
licit this effect (Fig. 5D). Similar results were obtained in
n AP-1 reporter assay with the coexpression of LMP2A
nd LMP1 inducing a twofold activation of AP-1 activity
elative to LMP1 alone and again this cooperative effect
as not evident with LMP2B (Fig. 5E).
To further substantiate these observations, electro-
horetic mobility shift assays (EMSAs) for determining
F-kB binding activity in transiently transfected SVK cells
and in stable A431 cell lines were used. At 48 h post-
196 DAWSON ET AL.FIG. 3. LMP2A localizes to the endosomal network in epithelial cells. A431 cells transduced with the LMP2A retrovirus were grown on Teflon-coated
microslides prior to fixation and immunostaining in situ and digital confocal microscopic analysis. In all cases, cells were dually stained for LMP2A
expression using the Ba LMP2 reference serum (A, D, G, and J) (visualized in green), or with monoclonal antibodies specific for CD63 (B), lysosomes
(E), Golgi (H), or CD151 (K) (visualized in red). Green and red images were captured separately by confocal microscopic analysis and overlaid to
determine colocalization (visualized in yellow) (C, F, I, and L).
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197LMP2A AUGMENTS LMP1 SIGNALINGtransfection, SVK cells transfected with LMP1 alone
showed increased NF-kB binding activity, which was
ugmented by cotransfection with LMP2A but not LMP2B
Fig. 6A). A431 cell lines in which LMP2A or LMP2B were
tably expressed singly or in combination with LMP1
onfirmed the observations made in the transient ex-
FIG. 4. LMP2A and LMP2B do not colocalize with LMP1 in epithelial c
retroviruses (B), or with LMP1 and LMP2B retroviruses (C) were culture
FIG. 5. LMP2A, but not LMP2B, augments LMP1-mediated activatio
oncentrations of (A) pSG5LMP1, (B) pSG5 LMP2A, or (C) pSG5 LM
(kBconA-Luc) and equivalent amounts of CMV-b-gal. Thirty-six hours
eporter assay. To examine possible cooperative effects between LMP
MP1, LMP2A, or LMP2B, either alone, or as combinations (0.1 mg ea
onstruct (E), and equivalent amounts of CMV-b-gal. Thirty-six hours po
ssay. Relative luciferase activity was calculated as the ratio of lucifera
eviation of three independent experiments.MP2 expression using CS1-4, a monoclonal antibody specific for LMP1 (Gr
reen and Red images were captured separately by confocal microscopic anression system. The basal levels of NF-kB binding ac-
ivity were similar between neo control and LMP2A- or
MP2B-expressing cells, whereas a significant increase
as observed in LMP1-expressing cells (Fig. 6B). When
oexpressed with LMP1, LMP2A, but not LMP2B, signif-
cantly enhanced NF-kB binding activity (Fig. 6B).
31 cells transduced with an LMP1 retrovirus (A), with LMP1 and LMP2A
flon-coated microslides and dual immunostained in situ for LMP1 and
-kB and AP-1. SVK cells were transiently transfected with increasing
constructs in the presence of a NF-kB luciferase reporter plasmid
nsfection, cells lysates were analyzed for NF-kB or AP-1 activity by
LMP2A/B, SVK cells were transiently transfected with 0.1 mg of pSG5
the presence of an NF-kB reporter construct (D), or an AP-1 reporter
ection, cell lysates were analyzed for NF-kB or AP-1 activity by reporter
-galactosidase activity and results are depicted as means 6 standardells. A4
d on Ten of NF
P2B
posttra
1 and
ch), in
sttransfeen), or LMP2A/B using the Ba human LMP2 reference serum (Red).
alysis and overlaid to determine colocalization (visualized in yellow).
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pared, and the degree of NF-kB binding activity assessed using a
32P-labeled HIV-kB probe.
198 DAWSON ET AL.Tyrosine residues that constitute the ITAM motif (Y74/
85) of LMP2A are critical for LMP2A-mediated
enhancement of LMP1 signaling
To define the regions of LMP2A responsible for aug-
menting LMP1-induced NF-kB activation, a series of
MP2A mutants were assayed for their ability to coop-
rate with LMP1 in transient reporter assays in SVK cells.
utants containing substitutions at tyrosine residues
74/85 (that constitute the ITAM motif of LMP2A) and
yrosine Y112 were chosen, as these tyrosine residues
ave previously been demonstrated as being critical
esidues for mediating LMP2A signaling events in B
ymphocytes (Longnecker, 2000). Similar to wild-type
MP2A, these mutants failed to induce NF-kB activation
irectly (Fig. 7). However, both the Y74/85 and the Y112
utants were severely impaired in their abilities to aug-
ent LMP1-mediated NF-kB activation. The LMP2A-
74/85 mutant was completely unable to cooperate with
MP1 in the activation of NF-kB, giving the same levels
f NF-kB activation as LMP1 alone or that of LMP1 with
MP2B (Fig. 7). The LMP2A-Y112 mutant showed a re-
uced cooperative effect with LMP1 compared to wild-
ype LMP2A, although this mutant produced a relative10-
old activation above that obtained with LMP1 alone
Fig. 7).
MP2A augments signaling from mutant LMP1
roteins
To investigate whether the ability of LMP2A to aug-
ent LMP1 signaling was differentially dependent on
ne or both major activating domains of LMP1, the effect
f LMP2A on the NF-kB activating capacity of LMP1
utants was examined. A panel of three previously de-
cribed LMP1 mutants were used: (i) a CTAR1-negative
utant, LMP1AAA, in which the TRAF-binding PxQxT motif
is disrupted by alanine substitutions; (ii) a CTAR2-nega-
tive mutant, LMP1378Stop, in which a stop codon at po-
sition 378 produces a truncated protein which is unable
to bind TRADD; and (iii) a double CTAR1-negative and
CTAR2-negative mutant, LMP1AAA/378Stop (Eliopoulos et
al., 1999). NF-kB reporter assays were performed in SVK
cells in which the LMP1 mutants were expressed singly
or in combination with LMP2A. As previously observed,
both CTAR1-negative and CTAR2-negative mutants were
impaired in their ability to activate NF-kB compared to
wild-type LMP1 (Fig. 8). In these experiments using SVK
cells the LMP1AAA mutant and the LMP1378Stop mutant
isplayed reduced NF-kB activity relative to wild-type
MP1, while double LMP1AAA/378Stop mutant was unable
o activate this pathway (Fig. 8). When either the LMP1AAA
mutant or the LMP1378Stop mutant was cotransfected
with LMP2A, significant augmentation of NF-kB activa-
tion was observed resulting in around three times the
activation achieved when these mutants were expressedFIG. 6. Electrophoretic mobility shift assay (EMSA) demonstrating
NF-kB binding activity in nuclear extracts isolated from (A) SVK cells
ransiently transfected with pSG5, pSG5LMP1, LMP2A, LMP2B,
lone, or in combinations, and (B) A431 cells stably expressing
MP1, LMP2A, LMP2B, or the neo resistance gene, or clones coex-
ressing LMP1 with LMP2A or LMP2B. Nuclear extracts were pre-alone. As expected, coexpression of LMP2A with the
double LMP1AAA/378Stop mutant did not raise this level
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199LMP2A AUGMENTS LMP1 SIGNALINGabove that of basal LMP2A-induced activity (Fig. 8). Thus,
the ability of LMP2A to augment LMP1-induced NF-kB
activation was not dependent on a specific domain of
LMP1, but rather reflected an innate ability of LMP2A to
increase the signaling capacity of both wild-type and
mutant forms of LMP1, irrespective of their relative sig-
naling defects.
LMP2A augments LMP1 signaling by increasing the
levels of LMP1 expression
The ability of LMP2A to augment LMP1 signaling could
occur through either a direct association leading to mod-
FIG. 7. Tyrosine residues that constitute the ITAM motif in the amino
signaling. SVK cells were transiently transfected with 0.1 mg pSG5 LMP1
r in combinations. Thirty-six hours posttransfection, cells lysates were
calculated as the ratio of luciferase vs b-galactosidase activity and
xperiments.
FIG. 8. LMP2A augments signaling from LMP1 mutants. SVK cells
MP1AAA/378stop either alone, or in combination with pSG5LMP2A, and e
osttransfection, cell lysates were analyzed for NF-kB activity by reporter ass
vs b-galactosidase activity and results are depicted as means 6 standard deification of the LMP1 signaling complex or an indirect
effect resulting in modulation of the stability and/or turn-
over of LMP1. As LMP1 and LMP2A appear to reside at
distinct regions within cells (Fig. 4), it is unlikely that
LMP2A is exerting this effect through direct association
with LMP1. To investigate the possibility that LMP2A may
modulate the stability or turnover of LMP1, the levels of
LMP1 protein expressed in the presence of LMP2A and
LMP2B were determined. SVK cells were transiently
transfected with a constant amount of LMP1 expression
vector (0.1 mg) and increasing amounts of either LMP2A
or LMP2B expression vector (0.01–3 mg) and immuno-
s of LMP2A are required for LMP2A-mediated augmentation of LMP1
A, LMP2B, or the pSG5LMP2A mutants, Y74/85, and Y112, either singly
ed for NF-kB activity by reporter assay. Relative luciferase activity was
are depicted as means 6 standard deviation of three independent
transiently transfected with 0.1 mg pSG5 LMP1, LMP1AAA, LMP1378stop,
mounts of NF-kB and CMV-b-gal reporter constructs. Thirty-six hoursterminu
, LMP2
analyzwere
qual aay. Relative luciferase activity was calculated as the ratio of luciferase
viation of three independent experiments.
e
f 1-4 m
m xperim
200 DAWSON ET AL.blotting with LMP1-specific CS1-4 mAbs was performed
48 h posttransfection. Increasing the amount of LMP2A
in the transfection was found to result in a significant
increase in the levels of LMP1 expression, even though
these experiments contained a constant amount of the
LMP1 plasmid (Fig. 9A, top). This effect was specific for
LMP2A, as increasing the amount of LMP2B with LMP1
did not show any effect on expression levels (Fig. 9B,
bottom). These blots were stripped and reprobed for
FIG. 9. LMP2A increases the level of LMP1 expression in transfect
increasing concentrations (0.01–3 mg) of (A) pSG5 LMP2A, (B) pSG5 LM
xtracts were made 48 h posttransfection, and equal amounts of total c
or the levels of LMP1 expression after Western blotting with the CS
onoclonal antibody specific for the HA epitope. Three independent eLMP2A and LMP2B and increasing expression of both
LMP2A (Fig. 9A, bottom) and LMP2B (Fig. 9B, bottom)with increased plasmid concentration was confirmed.
Probing of the blots with a monoclonal antibody against
cellular b-actin confirmed that equal amounts of cellular
protein were present in each sample (data not shown).
A similar ability of LMP2A to enhance the expression
of the LMP1 mutants including the signaling-defective
LMP1AAA/378Stop mutant was found (data not shown). To
map the region of LMP2A required for stabilizing LMP1
protein expression, cotransfection experiments with in-
. SVK cells were transiently transfected with 0.1 mg pSG5 LMP1 and
) pSG5LMP2A-Y74/85 mutant, and (F) pSG5LMP2A-Y112 mutant. Protein
tein (100 mg) resolved by SDS–PAGE. Resolved proteins were assayed
Ab, or for LMP 2A (C) and LMP2B expression (D) using the 12CA5
ents were performed and gave similar results.ed cells
P2B, (E
ell procreasing concentrations of the LMP2A-Y74/85 and
LMP2A-Y112 mutants were employed followed by immu-
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Y74/85 mutant was unable to increase LMP1 expression
(Fig. 9C), while an intermediate level of LMP1 protein
induction was observed with the LMP2A-Y112 mutant
(Fig. 9D).
LMP2A increases the half-life of LMP1
To determine whether LMP2A affects the turnover of
LMP1, pulse-chase experiments were performed in 293
cells transiently transfected with either LMP1 or LMP1
and LMP2A. Twelve hours after transfection, cells were
labeled for with 35S-methionine and harvested at 0, 2, 4,
6, and 9 h postlabeling for subsequent LMP1 immuno-
precipitation. Direct visualization of radiolabeled LMP1
revealed an extended half-life in the presence of LMP2A
(Fig. 10A). Subsequent densitometric analysis to deter-
FIG. 10. LMP2A increases the half-life of LMP1. Pulse-chase exper-
ments were performed in transiently transfected HEK 293 cells to
etermine the half-life of LMP1 in the presence or absence of LMP2A.
EK 293 cells were transiently transfected with 5 mg pSG5LMP1 or
pSG5LMP1 and pSG5LMP2A Twenty-four hours posttransfection the
cells were labeled in serum-free DME with the EXPRE35S35S mixture
NEN) for 1 h (zero time point). The cells were “chased” in the complete
MEM for indicated times. LMP1 was immunoprecipitated from cell
ysates using the CS.1 mAb and immunoprecipitates were analyzed by
DS–PAGE, autoradiography, and quantitation by densitometry. In two
ndependent experiments LMP1 was found to have a half-life of 2.2 6
.6 h, while in the presence of LMP2A this was increased to 4.0 6
.78 h.mine the strength of the signal relative to the control 0 h
time point allowed half-life calculations to be performed.Thus, the half-life of LMP1 expressed alone was 2.2 h but
in the presence of LMP2A this value was increased to
4 h (Fig. 10B). This piece of data was reproduced in three
different experiments and the increased half-life of LMP1
when coexpressed with LMP2A was also found in the
stable A431 LMP1/LMP2A cell line (data not shown).
Taken together these data indicate that the ability of
LMP2A to increase the expression of LMP1 is due to a
reduction in the turnover of LMP1 and that this extended
half-life results in enhanced LMP1 signaling.
DISCUSSION
The two EBV-encoded latent membrane proteins,
LMP1 and LMP2A/B, are frequently coexpressed in vi-
rus-associated tumors such as NPC, HD, and immuno-
blastic lymphoma (Brooks et al., 1992; Deacon et al.,
1993; Niedobitek et al., 1997; Rickinson and Kieff, 1996).
These proteins share a predicted integral membrane
topology and, in addition, their cytoplasmic domains
have been shown to associate with cell signaling mole-
cules (Eliopoulos and Rickinson, 1998; Longnecker,
2000). LMP1, the major transforming protein of EBV, ac-
tivates signal transduction cascades via recruitment of
the TRAF adaptor proteins, resulting in the activation of
NF-kB and the mitogen-activated protein (MAP) kinase
family (Devergne et al., 1996; Eliopoulos et al., 1999a,b;
Eliopoulos and Young, 1998; Izumi et al., 1997; Izumi and
Kieff, 1997; Kieser et al., 1997; Mosialos et al., 1995).
LMP1 also physically associates with members of the
Janus family of protein kinases (Jak), leading to activation
of signal transducers and activators of transcription
(STATs) (Gires et al., 1999). In contrast, LMP2A is not
essential for virus-mediated B cell transformation but is
able to block viral reactivation by sequestering signaling
proteins that are activated in response to BCR cross-
linking (Longnecker, 2000; Miller et al., 1994, 1995).
LMP2A recruits src kinase family members such as syk
and lyn and is also able to interact with the ERK1 MAP
kinase. In doing so, LMP2A may sequester these signal-
ing molecules, thereby making them unavailable to pu-
tative signaling receptors. Recent data also suggest that
in the correct setting, LMP2A may induce proliferation
and survival of B cells (Caldwell et al., 2000, 1998).
Although numerous studies have identified effects of
LMP1 expression on epithelial cell growth and pheno-
type, a functional role for LMP2A/B in such cells is yet to
be elucidated. One study has shown that LMP2A is
phosphorylated on tyrosine residues in response to ep-
ithelial cell adhesion but the phenotypic consequences
of this effect remain unknown (Scholle et al., 1999). In this
study we have identified a novel function for LMP2A in
augmenting LMP1 signaling via stabilization of the LMP1
protein. This observation is clearly relevant to the onco-
genic properties of LMP1 and the observation that many
LMP1-induced effects appear to be dose-dependent
(Johnson et al., 1998). The ability of LMP2A to enhance
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202 DAWSON ET AL.LMP1-induced activation of NF-kB and AP-1 is not direct,
s LMP2A is unable to activate these signaling pathways
hen expressed alone. However, when coexpressed
ith LMP1, LMP2A is clearly able to augment LMP1-
ediated activation of these signaling pathways in a
ose-dependent manner. The ability of LMP2A to en-
ance the signaling capacity of LMP1 mutants indicates
hat LMP2A does not require a complete or “functionally
ntact” LMP1 signaling complex, neither does it require a
articular facet of LMP1 signaling for this potentiation. A
ole for the cytosolic amino terminus of LMP2A in medi-
ting this effect is evidenced by the inability of LMP2B to
nhance LMP1 signaling. This does not preclude a mod-
latory role for LMP2B, perhaps by altering the stoichi-
metry of LMP2A homooligomers, as has previously
een suggested (Longnecker, 2000). Using a panel of
MP2A mutants carrying fine point mutations, the re-
ions of LMP2A critical for enhancing LMP1 signaling
ere identified. Our findings show that the same resi-
ues required for LMP2A-mediated effects in B cells are
lso important in augmenting LMP1 signaling in epithe-
ial cells (Fruehling et al., 1997, 1998). Tyrosine residues
ocated at positions 74 and 85 are absolutely essential
or this effect, whereas the tyrosine residue located at
osition 112 plays a contributory role. The Y74/85 resi-
ues constitute an ITAM motif, associate with the syk
yrosine kinase, and disrupt signaling from the BCR,
hereas Y112 associates with the lyn kinase and func-
ions to modulate activation of the LMP2A ITAM (Frueh-
ing et al., 1997, 1998). Although mutation of Y112 resulted
in a reduced ability of LMP2A to augment LMP1-induced
NF-kB activation, mutation of tyrosines Y74/85 rendered
LMP2A completely inert. These observations demon-
strate that the ITAM motif is an essential component of
LMP2A-mediated effects and suggest that signals trans-
duced or modulated via the ITAM are required for LMP2A
to augment LMP1 signaling. As both lyn and syk are
lymphoid-specific PTKs, the src kinase family member(s)
that associate with the LMP2A ITAM and with Y112 in
epithelial cells is presently unknown.
Although the precise mechanism by which LMP2A
modulates LMP1 signaling is unknown, our observations
suggest that rather than modulating the LMP1 signaling
complex directly, LMP2A influences LMP1 signaling by
increasing the stability and turnover of LMP1. Data to
support this hypothesis came from the findings that the
levels of LMP1 protein expression were significantly el-
evated in cells where LMP1 was coexpressed with
LMP2A but not in cells expressing LMP2B or the ITAM-
defective LMP2A-Y74/85 mutant. The ability of LMP2A to
increase expression of both biologically active and bio-
logically inactive LMP1 proteins suggests that LMP2A-
induced potentiation does not require the signaling prop-
erties of LMP1 but results from the ability of LMP2A to
directly alter the turnover of the LMP1 protein. This could
be explained by an effect of LMP2A on the efficiency of
LMP1 transcription or the stability of LMP1 transcripts.Alternatively, LMP2A could be stabilizing the LMP1 pro-
tein by influencing its degradation and/or turnover. Data
to support the latter possibility come from pulse-chase
analysis, which shows that the half-life of LMP1 almost
doubles in the presence of LMP2A. Thus, the extended
half-life of LMP1 results in increased levels of LMP1
protein with consequent enhancement of its signaling
capacity. Given the lack of a colocalization of LMP1 with
LMP2A described in this study, the effect of LMP2A on
LMP1 turnover is likely to be via an indirect mechanism
which affects the processes that mediate LMP1 turnover
and degradation. This possibility is supported by recent
work demonstrating that LMP1 is ubiquitinated (Aviel et
al., 2000), a particularly pertinent observation given the
role of this process in the turnover of certain growth
factor receptors (Hershko and Ciechanover, 1998). The
recent demonstration that LMP2A associates with mem-
bers of the Nedd4 ubiquitin ligase family of proteins
resulting in rapid turnover of LMP2A itself and of lyn
kinase is also of interest (Ikeda et al., 2000). By recruiting
ubiquitin ligase family members, LMP2A may modulate
the pathways responsible for LMP1 turnover and degra-
dation either by sequestering the ligases which target
LMP1 or by enhancing the degradation of factors which
negatively regulate this process. Further investigations
examining the impact of LMP2A on the extent and kinet-
ics of LMP1 ubiquitination are clearly warranted.
Additional clues to the mode of LMP2A action come
from the study of its localization within the epithelial cell.
In all cases, the immunofluorescent staining showed a
clear punctate, perinuclear distribution in subcellular
membranes that extended to endomembranes. Dual im-
munofluorescent staining localized LMP2A and LMP2B
predominantly to early/late endosomes and the lyso-
some compartments of epithelial cells. Although we can-
not exclude the possibility that small amounts of
LMP2A/B are present at the plasma membrane, negligi-
ble colocalization was observed with CD151, a tet-
raspanin protein that localizes to the plasma membrane
in epithelial cells (Berditchevski et al., 1996). This differs
significantly from B cells where LMP2A/B is localized to
numerous small patches in the plasma membrane. It is
unlikely that this difference reflects technical variation in
reagents or fixation procedures, as the same immuno-
staining approach using Ba serum on LMP2A- or
LMP2B-transfected B cells revealed plasma membrane
staining (C. W. Dawson, unpublished observations). Fur-
thermore, LMP2A/B did not colocalize with LMP1 as it
does in B cells (Longnecker and Kieff, 1990), even though
the plasma membrane distribution of LMP1 is preserved
between B cells and epithelial cells. Thus, cell type
specific differences in the localization of LMP2A/B may
exist resulting in interactions with distinct signaling pro-
teins. Consistent with these observations, preliminary
analysis of LMP2A expression in NPC biopsies reveals
strong cytoplasmic reactivity with no restriction to the
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203LMP2A AUGMENTS LMP1 SIGNALINGplasma membrane (G. Niedobitek, P. G. Murray, and L. S.
Young, unpublished observations).
The ability of LMP2A to affect LMP1 signaling despite
its intracellular location is not unusual. Previous work
has demonstrated that endosomal localization can have
a variety of effects on signaling pathways such as those
activated by epidermal growth factor (EGF), TNF-a, and
nsulin (Bevan et al., 1996). For example, the SHC adaptor
rotein associates with tyrosine-phosphorylated EGF re-
eptor at the plasma membrane and becomes tyrosine
hosphorylated itself. Following EGF stimulation, SHC is
apidly recruited into endosomes where, instead of being
eactivated, the tyrosine phosphorylation of SHC is in-
reased, leading to a prolonged activation of this protein
Bevan et al., 1996). A different mechanism is seen in the
NF-a pathway where a TNF receptor second messen-
er, ceramide, initiates the MAPK cascade when gener-
ted at the plasma membrane but leads to the activation
f the NF-kB pathway when produced from TNF receptor
at the endosomal membrane (Bevan et al., 1996). The
distribution of LMP2A is reminiscent of the BPV E5 pro-
tein which localizes to the Golgi and endoplasmic retic-
ulum membranes and, by translocation within these
compartments, modulates the phosphorylation and acti-
vation of growth factor receptors (Goldstein et al., 1992;
Sparkowski et al., 1995). It is possible that LMP2A could
be acting in a comparable way to one of these proteins
by affecting turnover or activity of cellular receptors that
are localized at the plasma membrane leading to altered
regulation of cell signaling pathways. In this scenario,
LMP2A would be expected to exert a more global effect
on cellular receptor signaling. Thus, it is interesting that
in preliminary experiments we have found that LMP2A is
able to augment TNF-a signaling but not that elicited
hrough the EGF receptor (C. W. Dawson and L. S. Young,
npublished observations). An important implication of
his finding is that LMP2A may serve to amplify signaling
hrough cellular receptors as well as LMP1 and thereby
ontribute to the oncogenic process. This is reminiscent
f the transforming ability of the BPV and HPV E5 pro-
eins which is dependent on an association with growth
actor receptors and results in enhanced signaling (Con-
ad et al., 1994; Riese and DiMaio, 1995). In conclusion,
e have identified a novel function of LMP2A in enhanc-
ng the expression and signaling capacity of LMP1 in
pithelial cells which, given the subcellular localization
f LMP2A, may have more general implications for the
nfluence of LMP2A on cellular receptor turnover. In fu-
ure studies it will be interesting to determine the effect
f LMP2A on other cellular receptors and to examine the
ole of src kinases in modulating LMP1 expression.
MATERIALS AND METHODS
Cell culture of A431, SVK, and EJ cell linesThe A431 and EJ cell lines was grown in DME (Gibco)
supplemented with 5% fetal calf serum (Gibco), 2 mM
i
tglutamine, and the antibiotics penicillin (1000 U/ml) and
streptomycin (1 mg/ml) (Sigma). The SVK cell line was
grown in Jocklics (Gibco) supplemented with 5% fetal calf
serum (Gibco), 2 mM glutamine, hydrocortisone (0.4 mg/
l) (Upjohn Ltd., U.K.), and the antibiotics penicillin (1000
/ml) and streptomycin (1 mg/ml) (Sigma). For routine
ulture, A431 and EJ cells were split at a 1:10 ratio, once
er week, and SVK cells at 1:5 ratio per week.
ransient transfection and luciferase reporter assays
For transient transfections, SVK cells were plated out
t 1.5 3 106 cells in a 25-cm2 flask (Nunc). The following
day, cells were transfected using a standard DEAE-dex-
tran transfection protocol (Khanim et al., 1997). SVK cells
were transiently transfected by DEAE-dextran method as
previously described. Luciferase reporter and b-galacto-
sidase were performed as described previously (Elio-
poulos et al., 1997). Briefly, between 0.01 and 3 mg of
SG5LMP1, or HA-tagged LMP2A and LMP2B expres-
ion vectors, were cotransfected with 3 mg luciferase
reporter plasmid and 1 mg control b-galactosidase plas-
mid (used to standardize for transfection efficiency).
Three micrograms each of a cytomegalovirus (CMV)-
driven expression plasmid and of the 3Enh.k BconA-Luc
reporter, which contains three tandem repeats of the
NF-k B sites from the IgGk promoter (Eliopoulos et al.,
1997), were routinely used to transfect SVK cells. The
AP-1 reporter plasmid was a kind gift from Dr D. Mc-
Cance. This was a collagenase-luciferase 273/163 con-
struct (Antinore et al., 1996). Analysis of luciferase and
b-galactosidase was performed 48 h post transfection.
Transduction of established cell lines with
amphotrophic retroviruses
Retrovirus packaging cell lines producing either
LMP2A, LMP2B, LMP1, or neomycin control or hygromy-
cin B retrovirus were obtained from Dr. G. Winberg (Karo-
linska Institute, Stockholm, Sweden). The construction of
the retroviral vectors and the generation of the producer
cell lines (PA317) has been detailed previously
(Berditchevski et al., 1996). The transduction of estab-
lished epithelial cell lines was achieved through cocul-
tivation of retroviral producing packaging cells and the
cell line of interest. Briefly, between 2 and 3 3 106
g-irradiated packaging cells were seeded onto 9-cm
petri dishes containing actively growing cells (20% con-
fluent) in growth medium containing 10 mg/ml hexad-
methrine bromide. After an overnight incubation, the
edium was removed and fresh growth medium added.
he g-irradiated packaging cells were removed by EDTA
washing 48 h post-cocultivation, and growth medium
containing G418 (400 mg/ml) was added. After 10 days of
rug selection, drug-resistant polyclonal populations
ere screened for expression of LMP2A or LMP2B byndirect immunofluorescence (see below). Drug-resis-
ant, polyclonal populations were then expanded in the
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204 DAWSON ET AL.presence of G418 (400 mg/ml). Subsequently cell lines
tably coexpressing LMP1 and LMP2A or LMP2B were
enerated by transducing the LMP2-expressing cell
ines with an LMP1 retrovirus carrying a hygromycin B
esistance marker using the packaging line as described
bove (Trivedi et al., 1991).
mmunofluorescent staining for LMP2A/B in situ
Actively growing cells were trypsinized and resus-
ended in normal growth media at a concentration of 2 3
05/ml. Fifty microliters of the suspension was pipetted
nto each well of a Teflon-coated microscope slide
Hendley) in a sterile petri dish and then incubated for
4 h at 37°C. The slides were washed in PBS and cells
ere fixed by immersion in 3% paraformaldehyde (PFA)
or 10 min, washed in PBS, and then permeabilized in
.5% Triton X-100 (in PBS) for 5 min. Primary antisera
human sera) were diluted 1:50 in 20% heat-inactivated
ormal goat serum (HINGS) and 15 ml added to each
microdot. Slides were then incubated for 45–60 min at
37°C before washing in PBS for 2 3 20 min. The sec-
ondary FITC-conjugated goat anti-human IgG (Sigma)
was also diluted in 20% HINGS, 15 ml added per mi-
rodot, and then incubated for 45–60 min at 37°C. Fol-
owing 2 3 20 min PBS washes, slides were mounted in
ABCO antifading agent and viewed under a light micro-
cope.
ubcellular localization of LMP2A: Two-color indirect
mmunofluorescence staining for LMP2A and
ubcellular organelles
A431 cells expressing LMP2A, LMP2B, LMP1, or con-
rol genes (neo/hyg) were immunostained in situ as de-
cribed above except that both the LMP2 reference se-
um and the primary monoclonal antibodies were diluted
ogether in 20% HINGS to the appropriate concentration.
onoclonal antibodies used in this study include the
ollowing: (i) 6H1, against the CD63 endosomal TM4
rotein; (ii) 8G6, against the CD151 plasma membrane
M4 protein; (iii) 2C2, against a lysosomal TM4 protein;
nd (iv) TGN38, against 58K Golgi (Sigma). The TM4
Abs were a kind gift from Dr. F. Berditchevski. Prior to
ounting in DABCO, the slides were incubated in PBS
ontaining DAPI (49, 6-diamidino-2-phenylindole; Sigma)
t a concentration of 0.2 mg/ml for 5 min; this counter-
tains the nuclei of cells. Slides are mounted in DABCO
ntifading agent and viewed under a confocal micro-
cope.
nalysis of LMP2A expression in stable A431 and EJ
ell lines
LMP2A expression was confirmed using standard im-
unoblotting procedures. Briefly, 100 mg of a total pro-
tein extract from each clone (equivalent to ;106 cells)
were separated on a 7.5% SDS–PAGE gel. Separated
proteins were electroblotted onto nitrocellulose mem-
p
kbranes and, after blocking for 2 h with PBS–Tween (0.1%)
containing 5% fat-free skimmed milk, incubated overnight
with 14B7, a rat monoclonal antibody specific for the
cytosolic amino terminus of LMP2A (Fruehling et al.,
1996; Niedobitek et al., 1997). After two 60-min washes in
PBS–Tween (0.1%), the nitrocellulose membrane was in-
cubated for 90 min with HRP-conjugated goat anti-rat
immunoglobulin (1:10,000) (Sigma). After two additional
60-min washes in PBS–Tween (0.1%), antibody–protein
complexes were visualized by ECL chemiluminescence
(Amersham).
Analysis of LMP1 and LMP2 expression in transiently
transfected SVK cells
LMP1 and LMP2 expression was confirmed using
standard immunoblotting procedures. Briefly, a total pro-
tein extract from each treatment (equivalent to ;106
cells) was separated on a 7.5% SDS–PAGE gel. Sepa-
rated proteins were electroblotted onto nitrocellulose
membranes and, after blocking for 2 h with PBS-Tween
(0.1%) containing 5% fat-free skimmed milk, incubated
overnight with primary antibodies specific for LMP1
(Rowe et al., 1987), HA (MBL Labs), or LMP2A (Fruehling
et al., 1996). After two 60-min washes in PBS–Tween
(0.1%), the nitrocellulose membrane was incubated for 90
min with either HRP-conjugated goat anti-mouse immu-
noglobulin (1:1000) (Sigma) or HRP-conjugated goat anti-
rat immunoglobulin (1:10,000) (Sigma). After an additional
two 60-min washes in PBS–Tween (0.1%), antibody–pro-
tein complexes were visualized by ECL chemilumines-
cence (Amersham).
Analysis of NF-kB and AP-1 complexes by
lectrophoretic mobility shift assay
Cultures of vector control, LMP1, LMP2A, and LMP2B-
xpressing clones or transiently transfected SVK cells
ere trypsinized and plated out at 2 3 106 cells/9 cm
late. The following day, cell nuclei were isolated by
esuspending cells in a solution containing 10 mM
EPES (pH 7.9), 1.5 mM magnesium chloride, 10 mM
otassium chloride, 0.5 mM DTT, and protease inhibitors
ere subjected to lysis in a buffer constituting 20 mM
EPES (pH 7.9), 25% glycerol, 1.5 mM magnesium chlo-
ide, 0.42 M sodium chloride, 0.2 mM EDTA, 0.5 mM DTT,
nd protease inhibitors. Protein concentration of isolated
uclear extracts was determined by the Bio-Rad protein
ssay according to manufacturers instructions. For elec-
rophoretic mobility shift assays a 29-bp HIV-kB probe
59-GATCAGGGACTT-TCCGCTGGGGACTTTCC-39) or a
2-bp collagenase TRE probe (59-AGCTTGATGAGTC-
GCCGGATC-39) were made by annealing complemen-
ary synthetic oligonucleotides and end-labeling using
g-[32P]ATP (Amersham) and T4 polynucleotide kinase
Boehringer). Binding reactions containing 10 mg nuclear
rotein extract, 1 mg poly(dIdC) (Pharmacia), 0.1 ng HIV-
B, or TRE probe labeled to a specific activity of 2 3 108
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205LMP2A AUGMENTS LMP1 SIGNALINGcpm/mg and binding buffer (4% glycerol, 1 mM EDTA, 5
M DTT, 0.01 M Tris–HCl, pH 7.5, and 5 mM KCl) in a
olume of 20 ml were incubated for 30 min at room
temperature and then resolved by electrophoresis
through a 5% polyacrylamide gel in a 0.553 TBE buffer.
Gels were then dried down and exposed to X-ray film for
autoradiography (Kodak).
Half-life determination by pulse chase labeling
Cells were transiently transfected using the calcium
phosphate method and left for 24 h posttransfection in
complete growth medium. After 24 h the cells were
washed twice in glutamine-, cystine-, and methionine-
free DME (Sigma) with added 5% glutamine. Next, 3 ml of
this medium was added to the cells and left at 37°C for
30 min. The protein was then labeled by replacing the 3
ml media with another 3 ml and adding 600 ml (6 mCi)
35S-protein labeling mix (EasyTagEXPRE35S35S; NEN).
his was left at 37°C for 1 h. After this stage, the cells
ere washed three times in the cystine/methionine-free
ME and then complete medium was added. The la-
eled cells were harvested at 0, 2, 4, 6, and 9 h time
oints. First they were washed three times in 3 ml ice-
old saline before being cell scraped into a universal.
he flask was washed again in 3 ml saline to remove any
emaining cells and this was also transferred to the
niversal. Cells were spun down at 1300 rpm for 5 min,
esuspended in 800 ml saline, and transferred to an
ppendorf. This was spun at 13,000 rpm for 10–15 s and
he supernatant removed. Pellets were frozen at 270°C.
o immunoprecipitate the required protein, the pellets
ere lysed in 300 ml RIPA buffer. Preclearance was done
at 4°C with 10 ml protein G beads (1:1 in PBS) and then
the supernatant incubated for 2 h with primary antibody
followed by 2 h with 25 ml protein G beads (1:1 in PBS).
All incubations were constantly mixed on a rotor wheel.
The beads were spun down at 4000 rpm for 2 min and
washed four times in RIPA buffer. The last wash of buffer
was removed with a 21 G syringe and 50 ml GSB added
before the sample was boiled for 5 min. The immuno-
precipitate was run on an acrylamide gel, Coomassie
stained for 15 min, and destained in destain I (45 ml
GDW, 45 ml methanol, 10 ml glacial acetic acid) for 1 h,
and then destained in destain II (90 ml GDW, 5 ml
methanol, 5 ml glacial acetic acid) for 1 h. The gel protein
was fixed and amplified using a half-hour shaken incu-
bation in Amplify reagent (Amersham). The gel was then
dried on a gel dryer for 40 min and exposed to Kodak
X-OMAT AR film before developing.
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